Marie-Claire Peakman is Executive Director, WRDM and Principal at Pfizer Ventures. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for supporting Pfizer’s investments in Arrakis Therapeutics, FoRx Therapeutics, Jnana Therapeutics, Levicept, Mediar Therapeutics, Palleon Pharma, ReCode Therapeutics, TRex Bio and Triplet Therapeutics.

Marie-Claire brings 23 years of scientific leadership at Pfizer, delivering small molecule therapeutics to the clinical and to market across multiple therapeutic areas. Most recently she led the Primary Pharmacology Group which she founded in 2009. She also has experience leading compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University.

Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.